Secondary prophylaxis of venous thromboembolism with direct oral anticoagulants: comparison between patients with major congenital thrombophilia versus non-thrombophilic patients

Direct oral anticoagulants (DOACs) are widely used for the treatment and secondary prophylaxis of venous thromboembolism (VTE). Congenital thrombophilia is a condition that predisposes to a higher incidence of VTE and often requires long-term anticoagulation for secondary prophylaxis. It is less cle...

Full description

Saved in:
Bibliographic Details
Published in:Internal and emergency medicine 2022-06, Vol.17 (4), p.1081-1085
Main Authors: Serrao, Alessandra, Assanto, Giovanni Manfredi, Mormile, Rosaria, Brescini, Mattia, Santoro, Cristina, Chistolini, Antonio
Format: Article
Language:English
Subjects:
Anticoagulants
Disease prevention
Hemorrhage
Im - Original
Internal Medicine
Medicine
Medicine & Public Health
Patients
Prophylaxis
Statistical analysis
Thromboembolism
Thrombophilia
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Direct oral anticoagulants (DOACs) are widely used for the treatment and secondary prophylaxis of venous thromboembolism (VTE). Congenital thrombophilia is a condition that predisposes to a higher incidence of VTE and often requires long-term anticoagulation for secondary prophylaxis. It is less clear the efficacy of DOACs in patients with major thrombophilia. The aim of our study was to evaluate the efficacy and safety of full and reduced DOACs dose for VTE secondary prophylaxis, in patients affected by major congenital thrombophilia compared to a control group of patients with idiopathic recurrent VTE without thrombophilia. We retrospectively evaluated consecutive patients who required long-term anticoagulation for recurrent VTE, treated with DOACs, and compared the outcomes between patients affected by major thrombophilia and the control group. The examined patients were 209. The median time of DOACs therapy was 20 months (range 6–90). Two (2.7%) thrombotic events were observed in the subset affected by major congenital thrombophilia ( n  = 72) and five (3.6%) in the control group ( n  = 137) ( p 0.73). Four (5.5%) hemorrhagic events were reported in the group with major thrombophilia; 21 (15.3%) in the other group ( p 0.039). No statistically significant differences were observed in terms of efficacy and safety between DOACs at full and reduced dose. Our data suggest that DOACs may be effective and safe in the secondary VTE prophylaxis in patients affected by major congenital thrombophilia, also at reduced dose.
ISSN:1828-0447
1970-9366
DOI:10.1007/s11739-021-02917-3